Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of 13-valent pneumococcal conjugate vaccine with routine infant vaccination in Italy
2005-004771-38Phase 3Completed
- Sponsor
- Wyeth
- Start
- Nov 2006
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pneumococcal disease comparing 13vPnC + Infanrix hexa with 7vPnC + Infanrix hexa (2 arms). Primary endpoints: Noninferiority of hepatitis B immune response after toddler dose and Safety profile of 13vPnC. Started Nov 2006; status: completed.
02
Drugs
pneumococcal 13-valent conjugate vaccinepneumococcal 7-valent conjugate vaccinepertussis filamentous haemagglutinin
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2005-004771-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004771-38.